Abstract:BackgroundThe conversion from estrogen-dependent to estrogen-independent state of ER+ breast cancer cells is the key step to promote resistance to endocrine therapies. Although the crucial role of MAPK/ERK signaling pathway in estrogen-independent breast cancer cell growth is well established, the underlying mechanism is not fully understood.MethodsIn this study, we profiled lncRNA expression against a focused group of lncRNAs selected from lncRNA database. CRISPR/Cas9 was employed to knockout (KO) linc-RoR in MCF-7 cells, while rescue experiments were carried out to re-express linc-RoR in KO cells. Colony formation and MTT assays were used to examine the role of linc-RoR in estrogen-independent growth and tamoxifen resistance. Western blot and qRT-PCR were used to determine the change of protein and lncRNA levels, respectively. The expression of DUSP7 in clinical specimens was downloaded from Oncomine (www.oncomine.org) and the dataset from Kaplan-Meier Plotter (http://kmplot.com) was used to analyze the clinical outcomes in relation to DUSP7.ResultsWe identified that linc-RoR functions as an onco-lncRNA to promote estrogen-independent growth of ER+ breast cancer. Under estrogen deprivation, linc-RoR causes the upregulation of phosphorylated MAPK/ERK pathway which in turn activates ER signaling. Knockout of linc-RoR abrogates estrogen deprivation-induced ERK activation as well as ER phosphorylation, whereas re-expression of linc-RoR restores all above phenotypes. Moreover, we show that the ERK-specific phosphatase Dual Specificity Phosphatase 7 (DUSP7), also known as MKP-X, is involved in linc-RoR KO-induced repression of MAPK/ERK signaling. Interestingly, linc-RoR KO increases the protein stability of DUSP7, resulting in repression of ERK phosphorylation. Clinical data analysis reveal that DUSP7 expression is lower in ER+ breast cancer samples than that in ER- breast cancer. Moreover, downregulation of DUSP7 expression is associated with poor patient survival.ConclusionTaken together, these results suggest that linc-RoR promotes estrogen-independent growth and activation of MAPK/ERK pathway of breast cancer cells by regulating the ERK-specific phosphatase DUSP7. Thus, this study might help not only in establishing a role for linc-RoR in estrogen-independent and tamoxifen resistance of ER+ breast cancer, but also suggesting a link between linc-RoR and MAPK/ERK pathway.

Correction To: Linc-ROR Facilitates Progression and Angiogenesis of Hepatocellular Carcinoma by Modulating DEPDC1 Expression

Linc-Ror Facilitates Hepatocellular Carcinoma Resistance To Doxorubicin By Regulating Twist1-Mediated Epithelial-Mesenchymal Transition

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

RETRACTED ARTICLE: the Lincrna-Ror/mir-145 Axis Promotes Invasion and Metastasis in Hepatocellular Carcinoma Via Induction of Epithelial-Mesenchymal Transition by Targeting ZEB2

Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK signaling pathway

Long Non-Coding RNA ROR Promotes Radioresistance in Hepatocelluar Carcinoma Cells by Acting As a Cerna for Microrna-145 to Regulate RAD18 Expression

LINC00152 Promotes Cell Cycle Progression in Hepatocellular Carcinoma Via Mir-193A/b-3p/ccnd1 Axis

LINC00152 Promotes Proliferation in Hepatocellular Carcinoma by Targeting EpCAM Via the Mtor Signaling Pathway

LINC02561 promotes metastasis in HCC via HIF1-α/NDRG1/UPF1 axis

Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma

LncRNA CRNDE promotes hepatoma cell proliferation by regulating the metabolic reprogramming of M2 macrophages via ERK pathway

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance

LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma.

A Novel Biomarker Linc00974 Interacting with KRT19 Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.

Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2

Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer

Bidirectional Transcription of Linc00441 and RB1 Via H3K27 Modification-Dependent Way Promotes Hepatocellular Carcinoma.

LINC00942 inhibits ferroptosis and induces the immunosuppression of regulatory T cells by recruiting IGF2BP3/SLC7A11 in hepatocellular carcinoma

LncRNA LINC01134 Contributes to Radioresistance in Hepatocellular Carcinoma by Regulating DNA Damage Response via MAPK Signaling Pathway

Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma